Privacy preference

MEDtalks would like to keep you informed about the content that is most relevant to you. Click here for more information.

ASCO GU 2018: Progression after IO combination regimens mRCC

Pedro Barata, experimental therapeutics clinical fellow at the Taussig Cancer Institute Cleveland Clinic, explains the design and results of the trial he presented during the poster session. This retrospective study examined the clinical outcome of patients with metastatic renal cell carcinoma progressing on frontline immune-oncology based combination regimens.

  • Sponsors

    This program is editorially independent and is financially supported by:

Related items